Human Epidermal Zinc Concentrations after Topical Application of ZnO Nanoparticles in Sunscreens. 2021

Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
Department of Physics and Astronomy & Earth and Planetary Sciences & Clinical Medicine, Macquarie University, Sydney 2109, Australia.

Zinc oxide nanoparticle (ZnO NP)-based sunscreens are generally considered safe because the ZnO NPs do not penetrate through the outermost layer of the skin, the stratum corneum (SC). However, cytotoxicity of zinc ions in the viable epidermis (VE) after dissolution from ZnO NP and penetration into the VE is ill-defined. We therefore quantified the relative concentrations of endogenous and exogenous Zn using a rare stable zinc-67 isotope (67Zn) ZnO NP sunscreen applied to excised human skin and the cytotoxicity of human keratinocytes (HaCaT) using multiphoton microscopy, zinc-selective fluorescent sensing, and a laser-ablation inductively coupled plasma-mass spectrometry (LA-ICP-MS) methodology. Multiphoton microscopy with second harmonic generation imaging showed that 67ZnO NPs were retained on the surface or within the superficial layers of the SC. Zn fluorescence sensing revealed higher levels of labile and intracellular zinc in both the SC and VE relative to untreated skin, confirming that dissolved zinc species permeated across the SC into the VE as ionic Zn and significantly not as ZnO NPs. Importantly, the LA-ICP-MS estimated exogenous 67Zn concentrations in the VE of 1.0 ± 0.3 μg/mL are much lower than that estimated for endogenous VE zinc of 4.3 ± 0.7 μg/mL. Furthermore, their combined total zinc concentrations in the VE are much lower than the exogenous zinc concentration of 21 to 31 μg/mL causing VE cytotoxicity, as defined by the half-maximal inhibitory concentration of exogenous 67Zn found in human keratinocytes (HaCaT). This speaks strongly for the safety of ZnO NP sunscreens applied to intact human skin and the associated recent US FDA guidance.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004817 Epidermis The external, nonvascular layer of the skin. It is made up, from within outward, of five layers of EPITHELIUM: (1) basal layer (stratum basale epidermidis); (2) spinous layer (stratum spinosum epidermidis); (3) granular layer (stratum granulosum epidermidis); (4) clear layer (stratum lucidum epidermidis); and (5) horny layer (stratum corneum epidermidis).
D005260 Female Females
D005452 Fluoresceins A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays. Tetraiodofluorescein
D005456 Fluorescent Dyes Chemicals that emit light after excitation by light. The wave length of the emitted light is usually longer than that of the incident light. Fluorochromes are substances that cause fluorescence in other substances, i.e., dyes used to mark or label other compounds with fluorescent tags. Flourescent Agent,Fluorescent Dye,Fluorescent Probe,Fluorescent Probes,Fluorochrome,Fluorochromes,Fluorogenic Substrates,Fluorescence Agents,Fluorescent Agents,Fluorogenic Substrate,Agents, Fluorescence,Agents, Fluorescent,Dyes, Fluorescent,Probes, Fluorescent,Substrates, Fluorogenic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D012869 Skin Absorption Uptake of substances through the SKIN. Absorption, Skin,Intracutaneous Absorption,Intradermal Absorption,Percutaneous Absorption,Transcutaneous Absorption,Transdermal Absorption,Absorption, Intracutaneous,Absorption, Intradermal,Absorption, Percutaneous,Absorption, Transcutaneous,Absorption, Transdermal,Absorptions, Intracutaneous,Absorptions, Intradermal,Absorptions, Percutaneous,Absorptions, Skin,Absorptions, Transcutaneous,Absorptions, Transdermal,Intracutaneous Absorptions,Intradermal Absorptions,Percutaneous Absorptions,Skin Absorptions,Transcutaneous Absorptions,Transdermal Absorptions

Related Publications

Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
April 2008, Journal of the European Academy of Dermatology and Venereology : JEADV,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
August 2020, The Journal of investigative dermatology,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
March 2023, Journal of photochemistry and photobiology. B, Biology,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
March 2004, The Journal of pharmacy and pharmacology,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
June 2003, Infection control and hospital epidemiology,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
July 1979, Cancer letters,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
March 2018, Toxicology and applied pharmacology,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
June 2020, ACS applied bio materials,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
June 2011, Journal of cataract and refractive surgery,
Zahra Khabir, and Amy M Holmes, and Yi-Jen Lai, and Liuen Liang, and Anand Deva, and Michael A Polikarpov, and Michael S Roberts, and Andrei V Zvyagin
March 2009, Toxicology letters,
Copied contents to your clipboard!